MINNEAPOLIS and
MARLBOROUGH, Mass., Jan. 5, 2022 /PRNewswire/ -- Bio-Techne
(NASDAQ: TECH), a global life sciences company providing innovative
tools and bioactive reagents for the research and clinical
diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ:
AKYA), The Spatial Biology Company®, today announced a partnership
to develop the first single-cell, spatial multiomics workflow for
comprehensive, unbiased analysis of tissue samples.
Through this agreement, the partners will bring to the market an
automated, spatial multiomics workflow that can perform rapid,
in situ analysis of multiple analytes, at single cell
resolution, across whole slides. Akoya's PhenoCycler-Fusion System,
due to launch in early January
2022, will run the company's well-established protein
imaging assays in addition to automating Advanced Cell
Diagnostics', a Bio-Techne brand, proven and highly cited RNAScope
HiPlex v2 assay for RNA imaging. The partnership exemplifies the
commitment of both companies to offer researchers greater access to
innovative and open access solutions for spatial biology
applications.
RNA and protein expression offer complementary insights into
cell states and phenotypes. Combining the PhenoCycler-Fusion
workflow with the RNAScope HiPlex v2 assay has the potential to
accelerate scientific understanding of human health and complex
diseases like cancer. Spatial multiomics approaches can also unlock
new biomarker diagnostic signatures, enabling better stratification
of patients and ultimately improving treatment outcomes.
Backed by over 4,500 peer-reviewed publications, RNAScope Assays
are an established standard for spatial RNA imaging. Under the
terms of the agreement, Bio-Techne and Akoya will develop and
co-market protocols to enable automated workflows for running
RNAScope assays on Akoya's spatial phenotyping systems.
This new combined workflow complements Akoya's spatial
transcriptomics capabilities, currently under development, serving
as an important validation tool for deep spatial phenotyping
applications.
"We are excited to partner with Akoya to accelerate multiomic
spatial phenotyping in translational and clinical disease
research," said Kim Kelderman,
President of Bio-Techne's Diagnostics and Genomics Segment.
"Akoya's established leadership in spatial phenotyping automation
and multiplex protein biomarker imaging is uniquely complementary
to Bio-Techne's proven expertise in specific and sensitive
multiplex RNA detection in cells and tissues. Enabling Akoya's
large and rapidly growing installed base with an automated HiPlex
RNAScope workflow provides a uniquely powerful solution to advance
discovery research and diagnostic assay development across a wide
range of diseases."
"The life sciences market has long needed an approach that
provides an unbiased, multiomics view of tissue biology and
architecture, which is critical for understanding complex
mechanisms of disease and response to therapy," said Brian McKelligon, Chief Executive Officer of
Akoya Biosciences. "The partnership with Bio-Techne, which
revolutionized RNA in situ hybridization methods, can
further empower researchers with the spatial tools and technologies
required to ignite innovation, and break barriers to advance
discovery of new biomarkers and improve treatment options."
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $931
million in net sales in fiscal 2021 and has approximately
2,700 employees worldwide. For more information on Bio-Techne and
its brands, please visit http://www.bio-techne.com.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences' (NASDAQ:
AKYA) mission is to bring context to the world of biology and human
health through the power of spatial phenotyping. The company offers
comprehensive single-cell imaging solutions that allow researchers
to phenotype cells with spatial context and visualize how they
organize and interact to influence disease progression and
treatment response. Akoya offers two distinct solutions, the
CODEX® and Phenoptics™ platforms, to serve the diverse needs
of researchers across discovery, translational and clinical
research. To learn more about Akoya,
visit www.akoyabio.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains "forward-looking statements" under
applicable securities laws. In some cases, such statements can be
identified by words such as: "may," "will," "could," "would,"
"should," "expect," "intend," "plan," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "continue,"
"ongoing" or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain
these words. Forward-looking statements include express or implied
statements regarding our ability to achieve our business
strategies, growth, or other future events or conditions. Such
statements are based on our current beliefs, expectations, and
assumptions about future events or conditions, which are subject to
inherent risks and uncertainties, including the risks and
uncertainties discussed in the filings we make from time to time
with the Securities and Exchange Commission. Actual results may
differ materially from those indicated in forward-looking
statements, and you should not place undue reliance on them. All
statements herein are based only on information currently available
to us and speak only as of the date hereof. Except as required by
law, we undertake no obligation to update any such statement.
Bio-Techne Investor Contact :
David Clair,
Sr. Director, Investor Relations and Corporate Development
Bio-Techne Corporation
612-656-4416
David.clair@bio-techne.com
Akoya Biosciences Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences
investors@akoyabio.com
Akoya Biosciences Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-akoya-biosciences-partner-to-deliver-automated-spatial-multiomics-workflow-with-industry-leading-speed-and-resolution-301454065.html
SOURCE Bio-Techne Corporation